183 related articles for article (PubMed ID: 36882165)
1. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
2. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
3. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
4. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
[TBL] [Abstract][Full Text] [Related]
5. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
6. ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
Jin F; Yang Z; Shao J; Tao J; Reißfelder C; Loges S; Zhu L; Schölch S
Trends Mol Med; 2023 Aug; 29(8):646-658. PubMed ID: 37179132
[TBL] [Abstract][Full Text] [Related]
7. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
8. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
[TBL] [Abstract][Full Text] [Related]
9. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
10. The Role of the AT-Rich Interaction Domain 1A Gene (
Li JJ; Lee CS
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
[TBL] [Abstract][Full Text] [Related]
11. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic significance of ARID1A mutation in bladder cancer.
Conde M; Frew IJ
Neoplasia; 2022 Sep; 31():100814. PubMed ID: 35750014
[TBL] [Abstract][Full Text] [Related]
13. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutations in cancer: another epigenetic tumor suppressor?
Wu JN; Roberts CW
Cancer Discov; 2013 Jan; 3(1):35-43. PubMed ID: 23208470
[TBL] [Abstract][Full Text] [Related]
15. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
16. The emerging roles of ARID1A in tumor suppression.
Wu RC; Wang TL; Shih IeM
Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract][Full Text] [Related]
18. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
20. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]